Clinical Trial Update: Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria [Phase 3]

View source ↗

Summary

Phase 3 trial of aztreonam for inhalation in children with cystic fibrosis and new Pseudomonas aeruginosa infection was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Respiratory Tract Infection Colonization

Drugs mentioned

• Aztreonam for Inhalation (aztreonam)

Snippet

Sponsor: Gilead Sciences | Conditions: Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2022-05-16